buy signalled again

Wedbush says Medicare decision positive for ventricular device makers
In a note to investors, Wedbush analysts Dr. Duane Nash and Akiva Felt wrote that weakness in providers of left ventricular assist devices - including Thoratec (THOR), HeartWare (HTWR), and WorldHeart (WHRT) - could create an attractive entry point for investors. Although Medicare decided not to expand reimbursement for the devices to Class IIIB patients as anticipated by Wedbush, the firm believes that the agency did make other changes that are positive for the device makers. These changes will allow left ventricular assist devices to be implanted more quickly and with less paperwork ,according to Wedbush. The firm expects HeartWare to rebound most quickly, while it recommends Thoratec for longer-term investors. Wedbush sees WorldHeart as attractive, but riskier. In early trading, Thoratec gained 1.50% to $34.40, while WorldHeart was flat at $2.27 and HeartWare fell 1.33% to $63.58. :theflyonthewall.com